Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5884 - Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Yali Li

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

Y. Li1, J.X. Sun1, J. Skoletsky1, C. Milbury2, C. Burns1, W. Yip3, N. Dewal4, J. He1, J. Tuesdell5, E. Peters6, E. Schleifman7, J. Noe8, S. Jenkins9, J.A. Elvin4, G. Otto1, D. Lipson10, J.S. Ross4, V.A. Miller4, M. Doherty1, C. Vietz1

Author affiliations

  • 1 Product Development, Foundation Medicine, Inc., 02141 - Cambridge, MA/US
  • 2 Product Development, Foundation Medicine, 02141 - Cambridge/US
  • 3 Product Development, Foundation Medicine, MA 02141 - Cambridge/US
  • 4 Genetics, Foundation Medicine, Inc., Cambridge/US
  • 5 Product Marketing, Foundation Medicine, Inc., 02141 - Cambridge, MA/US
  • 6 Companion Diagnostics, Genentech, Inc., San Francisco/US
  • 7 Companion Diagnostic Development, Oncology Biomarker Development, Genentech, Inc., South San Francisco/US
  • 8 Oncology Biomarker Development, Hoffmann La Roche, 4070 - Basel/CH
  • 9 Personalised Medicine And Biomarkers, Astrazeneca, SK10 4TG - Macclesfield/GB
  • 10 Other Institution, Foundation Medicine, 02141 - Cambridge/US
More

Resources

Abstract 5884

Background

Due to the compelling predictive value of companion diagnostic (CDx) biomarkers tied to targeted and immune-based therapies, well-characterized robust analytic and clinical validation of genomic assays has become mandatory. An NGS-based CGP (comprehensive genomic profiling) platform was developed in compliance with FDA guidelines for CDx indications.

Methods

DNA extracted from FFPE tumor tissue underwent whole-genome shotgun library construction and hybridization-based capture, followed by sequencing using Illumina HiSeq 4000. Sequence data were processed using a proprietary analysis pipeline designed to identify sub substitutions, indels, copy number alterations, genomic rearrangements, microsatellite instability (MSI), and tumor mutational burden (TMB) in 324 genes.

Results

Clinical validity was demonstrated by establishing statistical non-inferiority between CGP and the respective approved CDx, e.g. cobas EGFR and BRAF mutational testing, ALK rearrangements with FISH and IHC, ERBB2 amplification with FISH, and others. For analytical validity, concordance with an orthogonal NGS platform was 94.6% for substitutions and indels, and within-assay reproducibility had positive percent agreement (PPA) of 99.4%. TMB was analytically validated via concordance with whole-exome sequencing. For the first 616 patients (25% non-small cell lung cancer) assayed in clinical care, 6.8% of cases had TMB exceeding 20 mut/Mb, with 25% of these also harboring microsatellite instability. For 143 NSCLC cases, >50% harbored 10 mut/Mb. Of 354 cases with CDx findings possible, 25.6% had such findings, which were split nearly evenly between indications to benefit from and contraindications to targeted therapies.

Conclusions

We developed a CGP assay and demonstrated clinical and analytical validity for CDx biomarkers for targeted therapy, with clinical validation for TMB in progress via correlation with prospective immunotherapy trials. Initial oncologist feedback indicates impact of assay results on course of treatment decisions in patient care.

Clinical trial identification

Legal entity responsible for the study

Foundation Medicine, Inc.

Funding

Foundation Medicine, Inc.

Editorial Acknowledgement

Disclosure

Y. Li: Employee of and stockholder: Foundation Medicine Inc. J.X. Sun: Stockholder: Foundation Medicine Inc. J. Skoletsky, C. Milbury, C. Burns, W-K. Yip, N. Dewal, J. He, J. Tuesdell, J.A. Elvin, G. Otto, D. Lipson, J.S. Ross, V.A. Miller, M. Doherty, C. Vietz: Employee and stockholder: Foundation Medicine Inc. E. Peters, E. Schleifman, J. Noe: Employee and stockholder: Genentech Inc. S. Jenkins: Employee and stockholder: AstraZeneca.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings